Skip to main content
Premium Trial:

Request an Annual Quote

MDS Closes $615M Molecular Devices Acquisition

NEW YORK (GenomeWeb News) — MDS today said it has closed its $615-million acquisition of Molecular Devices.
 
MDS is using the purchase to create a new segment, MDS Analytical Technologies, which is a hybrid of Molecular Devices and the MDS Sciex business.
 
MDS Sciex President Andy Boorn will lead the new business unit.
 
With the deal, Molecular Devices’ stock was delisted yesterday from the Nasdaq Global Select Market. 
 
The two businesses had combined revenues of $432 million last year, and MDS expects Molecular Devices to contribute $190 million in revenue over the coming year, the company said in January.
 
MDS said at the time that its Sciex business will continue its mass spectrometry partnerships with Applied Biosystems and PerkinElmer. 

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more